Pleural Mesothelioma
Symptoms, diagnosis, staging and treatment options.
Overview
Pleural mesothelioma represents roughly 85% of all mesothelioma cases and accounts for roughly 3,000 new cases per year in the United States. Pleural mesothelioma involves the pleura, which is a thin, protective layer of mesothelial tissue covering the lungs (visceral pleura) and lining the interior wall of the chest cavity (parietal pleura). Pleural mesothelioma is caused by inhalation of asbestos fibers that travel to the lungs and become embedded in the pleura. The time from inhalation of asbestos fibers to the development of pleural mesothelioma (latency period) is typically 20-50 years.
Symptoms
Initial symptoms of pleural mesothelioma may be general and resemble those associated with more common conditions such as pneumonia or COPD, which contributes to late diagnosis. Common symptoms of pleural mesothelioma include:
Symptoms will vary from patient to patient depending on a variety of factors.
-
Chest pain – Often dull or aching, felt in the side or lower back
-
Shortness of breath – Frequently caused by pleural effusion (fluid buildup around the lungs in the pleural space between the visceral and parietal pleurae)
-
Persistent cough or wheezing
-
Fatigue and general weakness
-
Unexpected weight loss and loss of appetite
-
Fever or night sweats
-
Difficulty swallowing
Diagnosis
Diagnosing pleural mesothelioma usually involves several steps, since symptoms can overlap with other conditions. Imaging tests are often the first steps in diagnosing pleural mesothelioma and may include:
-
Chest X-ray – Can show pleural thickening or fluid.
-
Chest CT Scan with Contrast – Provides detailed views of the pleura and extent of disease.
-
Chest PET Scan – Helps assess spread and distinguish cancerous from benign tissue.
-
Chest MRI – Sometimes used to evaluate invasion into the chest wall or diaphragm.
Following imaging, the next steps in diagnosing pleural mesothelioma is obtaining fluid and tissue samples. If pleural effusion (fluid buildup in the pleural space) is present, thoracentesis (draining pleural fluid with a needle to test for cancer cells) will often be performed. Thoracentesis acts as both a symptom-relief treatment by draining excess fluid that restricts the lungs, and serves as an initial diagnostic tool by providing samples to a laboratory for cytological examination (where a pathologist studies the cells under a microscope to look for malignant, cancerous cells). Due to the difficulty of diagnosing mesothelioma, fluid cytology on its own typically does not confirm pleural mesothelioma.
The definitive test for diagnosing pleural mesothelioma is a tissue biopsy, which range from minimally invasive needle approaches to surgical procedures depending on how much tissue is needed, where the disease is and the patient’s fitness for a procedure:
-
Video-Assisted Thoracoscopic Surgery (VATS) – Requires general anesthesia, but widely considered the gold-standard method for diagnosis, allowing direct visualization of the pleura, targeted sampling of abnormal areas and larger tissue yield.
-
Image-Guided Percutaneous Needle Biopsy – Minimally invasive and often done under local anesthesia; good for accessible areas of pleural thickening, but less reliable when disease is patchy or small-volume.
-
Pleuroscopy/Medical Thoracoscopy – A less invasive cousin of VATS, often done under sedation and local anesthesia that allows for direct visualization and good-sized biopsies
-
Thoracotomy – The most invasive procedure that is used less often today and reserved for cases where thoracoscopy isn’t feasible/adequate or when more extensive surgical assessment is needed.
Staging
Staging is how doctors describe the size of a cancer and how far it has spread. Following a diagnosis of pleural mesothelioma, treatment decisions will in large part depend on the stage of the disease. Developed by the International Association for the Study of Lung Cancer (IASLC), the current 9th edition TNM classification system for pleural mesothelioma is the standard staging guideline used by doctors to guide prognosis and treatment. The TNM system classifies cancer by three components:
-
T – The Tumor: how large it is and what nearby areas it has reached
-
N – The Nodes: whether cancer has spread to nearby lymph nodes
-
M – Metastasis: whether cancer has spread to distant parts of the body
These combine into an overall stage, usually written as Stage I through Stage IV. In general, lower stages mean the cancer is smaller and more contained, while higher stages mean it has spread more widely.
The T category of the 9th Edition TNM classification system for pleural mesothelioma breaks down into four sub-categories that are mostly based on a tumor thickness measure (Psum) that is the sum of maximum pleural thickness measured at three levels of the chest (upper, middle and lower). The measurement-based categories that separate T1-T3 are appoximately:
-
T1 – Psum under approximately 12 millimeters (smallest tumor burden
-
T2 – Psum in the approximately 12-30 millimeter range, or thinner tumor with certain features like fissure involvement, mediastinal fat invasion or a single area of chest-wall invasion
-
T3 – Psum above approximately 30 millimeters (with locally advanced, but still potentially resectable features)
-
T4 – The most advanced local invasion, defined by what the tumor invades rather than thickness and carries a distinctly worse prognosis regardless of thickness
The N category of the 9th Edition TNM classification system for pleural mesothelioma breaks down into three sub-categories based on the extent of spread to the lymph nodes:
-
N0 – No regional lymph node involvement and part of what defines the earliest stages
-
N1 – Cancer has spread to the lymph nodes on the same side (ipsilateral) as the primary tumor within the chest
-
N2 – Cancer has spread to the lymph nodes on the opposite side (contralateral) of the chest or to nodes above the collarbone
The M category of the 9th Edition TNM classification system for pleural mesothelioma describes whether the cancer has spread to distant parts of the body beyond the chest:
-
M0 – No distant spead
-
M1 – Cancer has spread to distant organs or areas
The T, N and M categories combine into an overall stage from I to IV that break down into four categories:
-
Stage I – T1, N0, M0
-
Stage II – T1,N1 or T2, N0
-
Stage IIIA – T1, N2; T2 N1 or N2; any T3
-
Stage IIIB – any T4 (any N)
-
Stage IV – any M1 (any T or N)
The TNM classification system for pleural mesothelioma has two distinct types:
-
Clinical Staging (cTNM) – The assessment doctors make using the information available without operating (from scans, a physical exam and a biopsy). This is what most patients hear first, and for many it’s the main way their cancer is described because not everyone has the kind of surgery that would produce the second type of staging.
-
Pathological Stage (pTNM) – This assessment is determined after surgery – if surgery is done – when a pathologist examines the actual tissue and lymph nodes that were removed. Pathological staging is only available for patients who have surgery as part of their treatment plan.
Treatments
Once a diagnosis of pleural mesothelioma is confirmed, management by an experienced, multidisciplinary team (thoracic surgeon, thoracic medical oncologist, thoracic radiation oncologist, pulmonologist, radiologist and pathologist) at a specialized mesothelioma center is crucial. Treatment options will vary based on the clinical assessment of the diagnosis. Patients with early stage, epithelioid pleural mesothelioma will have different treatment options than patients with late stage, sarcomatoid or biphasic pleural mesothelioma.
Chemotherapy/Immunotherapy
Chemotherapy alone has been one of the backbones of mesothelioma treatment. For advanced/unresectable pleural mesothelioma, the combination of platinum plus antifolate was the standard of care until immunotherapy revolutionized the treatment of pleural mesothelioma in 2026. These therapies will be administered by thoracic medical oncologists:
-
Carboplatin (Paraplatin) or Cisplatin (Platinol) Plus Pemetrexed (Alimta) – This “platinum doublet” chemotherapy pairing has been the cornerstone of first-line treatment since 2004. Carboplatin is gentler than Cisplatin and is often used for older or less fit patients.
-
Ipilimumab (Opdivo) Plus Nivolumab (Yervoy) – A dual immune checkpoint blockade that helps the immune system recognize and attack the tumor, rather than attacking cancer cells directly like chemotherapy. This dual immunotherapy combination is strongly recommended for sarcomatoid and biphasic pleural mesothelioma, which have historically responded poorly to chemotherapy.
-
Carboplatin (Paraplatin) or Cisplatin (Platinol) Plus Pemetrexed (Alimta) Plus Pembrolizumab (Keytruda) – FDA-approved in 2024, this chemo-immunotherapy combination adds an immunotherapy boost to the familiar chemotherapy backbone and is appealing for epithelioid pleural mesothelioma or for patients where the treatment team wants chemotherapy’s direct tumor activity alongside immune activation.
-
Carboplatin (Paraplatin) or Cisplatin (Platinol) Plus Pemetrexed (Alimta) Plus Bevacizumab (Avastin) – Can sometimes extend survival in eligible patients when added to the traditional platinum doublet
-
Carboplatin (Paraplatin) or Cisplatin (Platinol) Plus Gemcitabine (Gemzar) – Sometimes offered when a patient can’t take Pemetrexed due to contraindications, intolerance or cost considerations.
-
Vinorelbine (Navelbine) – Typically offered second-line once a patient progresses on platinum doublet chemotherapy, but may be offered first-line to pleural mesothelioma patients who can’t tolerate or aren’t good candidates for platinum doublet chemotherapy or immunotherapy.
-
Pemetrexed (Alimta) – Sometimes offered second-line as maintenance monotherapy to continue disease control or first-line for selected elderly patients or those unfit for platinum doublet chemotherapy and immunotherapy.
-
Hyperthermic Intrathoracic Chemotherapy (HITHOC) – Always done in conjunction with surgery, HITHOC delivers heated chemotherapy (typically Cisplatin-based) directly into the pleural cavity to kill microscopic disease left behind after surgery.
-
Pressurized Intrathoracic Aerosol Chemotherapy (PITAC) – An early-stage, experimental procedure that is not combined with surgical removal of the main tumor. PITAC delivers chemotherapy as a pressurized aerosol mist into the pleural cavity via a special device, which spreads it evenly across the chest surfaces and helps it penetrate tumor tissue.
Surgery
Surgery for pleural mesothelioma falls into two broad categories – operations intended to treat the cancer (usually part of a multimodal therapy) and procedures aimed at relieving symptoms. Whether surgery is even an option depends heavily on cell type (epithelioid does best), disease stage and the patient’s overall fitness. Any surgical intervention will be performed by thoracic surgeons.
Cancer-directed (curative-intent) surgery can be an option for earlier-stage epithelioid disease and is almost always combined with chemotherapy and sometimes radiation or immunotherapy (in the clinical trial setting):
-
Pleurectomy/Decortication (P/D) – Removes the diseased pleura and any visible tumor, but spares the lung. An “extended” P/D (eP/D) also removes part of the diaphragm and/or the pericardium (heart lining) when involved. This is the favored surgical intervention for pleural mesothelioma because it preserves lung function.
-
Extrapleural Pneumonectomy (EPP) – A radical operation that removes the entire lung on the affected side, along with the pleura, part of the diaphragm and the pericardium (which is reconstructed with a patch). EPP removes more tissue, but carries a higher risk, greater impact on quality of life and high morbidity compared to P/D.
Palliative/symptom-relieving procedures don’t aim to remove all cancer, but improve comfort mainly by controlling recurrent pleural fluid:
-
Indwelling Pleural Catheter (IPC) – A tunneled catheter left in place so the patient can drain fluid at home over time.
-
Partial Pleurectomy – Removing enough tissue to relieve fluid buildup or trapped lung without attempting complete tumor removal.
Radiation Therapy
Radiation therapy in pleural mesothelioma is difficult to deliver because the pleura is a thin sheet wrapping the entire lung, so treating all of it means irradiating a large, curved area right next to radiosensitive organs. Since radiation is limited by the sensitivity of surrounding organs like the lungs and heart, it is almost never the main treatment and is instead used sparingly in specific roles, mainly palliation. Radiation treatment decision are made by thoracic radiation oncologists.
-
Palliative radiation – For symptom control, targeted radiation can shrink painful tumor deposits and relieve symptoms such as a painful chest-wall mass or nodule.
-
Adjuvant Radiation (after surgery) – For patients who have undergone an ePD or PD, radiation therapy is difficult and risky. It is therefore, rarely used in this setting. Radiation therapy played a larger role in patients who underwent an EPP because removal of the whole lung allowed delivery of radiation to the entire hemithorax without an intact lung in the way, but the EPP is almost never performed on patients with pleural mesothelioma in 2026.
-
Neoadjuvant Radiation (before surgery) – Some specialized centers give radiation therapy followed by surgery, but this approach remains investigational rather than standard.
Clinical Trials
In large part due to clinical trials, the landscape for the treatment of pleural mesothelioma has changed more in the past six years then in the previous thirty. Because the standard treatment options for pleural mesothelioma are so limited – especially at the second-line, where there’s no approved standard therapy, trial enrollment is a compelling option for many patients. Due to the rarity of mesothelioma, much of the strongest future treatment evidence comes through trials, and access to the newest approaches often only comes through them. Pleural mesothelioma patients interested in exploring clinical trial options are encouraged to search for “pleural mesothelioma” on www.clinicaltrials.gov.
A note about this information
This information is general and educational, and isn’t a substitute for advice from a qualified medical professional. Anyone facing a mesothelioma diagnosis should discuss their specific situation with their care team.
We’re here to help.
Connect with Mesothelioma Options for help and support.
Help, hope and support.
You don’t have to navigate this alone. Contact Mesothelioma Options.